Showing results filtered by:
133 Results
The Mosquito Immunity and Vector Competence Section investigates the interactions between the mosquito immune system and Plasmodium parasites to understand how they affect malaria transmission.
Last Reviewed: September 23, 2022
ABU aims to study antibody responses to infectious pathogens at the monoclonal level. Major goals: 1) develop new antibody therapeutics or prophylactics to combat infectious disease, 2) study antibody responses to immunization and infection at high resolution, 3) investigate the use of monoclonal antibodies as tools for immunogen design.
Last Reviewed: February 20, 2025
NBBTP/IRTA Fellows are trained specifically to support high containment research environments. Upon graduating from the program, NBBTP/IRTA alumni begin work as biorisk professionals with the knowledge and skills necessary to meet the scientific, regulatory, biocontainment, biosafety, engineering, communications, management, and public relations challenges associated with the conduct of research
Last Reviewed: January 21, 2025
Patrick E. Duffy, M.D., is Chief of the Laboratory of Malaria Immunology and Vaccinology, the Vaccine Development Unit, and the Pathogenesis and Immunity Section. The Pathogenesis and Immunity Section conducts human and animal studies of malaria pathogenesis and host immunity, including population-based studies in communities exposed to Plasmodium falciparum. Our research emphasizes pregnant women and children, the populations most susceptible to malaria morbidity and mortality, with collaborative cohort studies ongoing in Mali, Liberia and Guinea.
Last Reviewed: March 11, 2025
LBS has made numerous contributions to understanding cell biology of antigen processing and presentation by MHC class I and especially class II molecules. It also has examined recognition of these ligands by T cells with a focus on the signaling mechanisms involved in ligand discrimination. Various imaging technologies are used with more conventional molecular and cellular immunological methods.
Last Reviewed: September 30, 2022
The 206 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Tuesday, January 30, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1
Last Reviewed: May 21, 2024
The Division of Intramural Research (DIR), a component of the National Institute of Allergy and Infectious Diseases, has long been at the forefront of research on immunologic, allergic, and infectious diseases. For more than 60 years, DIR scientists have discovered new pathogens, deciphered normal immune system function, identified aberrations underlying immunological diseases, and developed FDA
Last Reviewed: June 6, 2024
LMIV Vaccine Development Unit develops and performs clinical evaluation of prototype malaria vaccines. The VDU focuses on research to eradicate malaria through development of a vaccine to interrupt malaria transmission, including transmission-blocking components and pre-erythrocytic components. The VDU also designs and develops vaccines specifically to protect pregnant women and their infants.
Last Reviewed: November 21, 2022